NasdaqCM - Nasdaq Real Time Price ? USD NeuroMetrix, Inc. (NURO) Follow Compare 3.9345 -0.0655 (-1.65%) As of 1:14 PM EDT. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations NeuroMetrix Reiterates its Review of Strategic Alternatives WOBURN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today for the purpose of clarity, reiterated that the Company is engaged in a review of strategic alternatives. In February of this year, the Company announced that it had initiated a review of strategic options with an objective of enhancing shareholder value. Over the past 6 months, the Company has invested considerable effort in evaluating a number of specific strategic directions and also making financial, oper GlobeNewswire ? 2 months ago NURO -1.65% NeuroMetrix Second Quarter 2024 Earnings: US$0.75 loss per share (vs US$1.56 loss in 2Q 2023) NeuroMetrix ( NASDAQ:NURO ) Second Quarter 2024 Results Key Financial Results Revenue: US$769.1k (down 54% from 2Q... Simply Wall St. ? 2 months ago NURO -1.65% NeuroMetrix Reports Q2 2024 Business Highlights and Update on Review of Strategic Options WOBURN, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and six months ended June 30, 2024. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. In February of this year, the Company announced that it had initiated a review of strategic options with an objective of enhancing shareholder value. Over the past six months, t GlobeNewswire ? 2 months ago NURO -1.65% NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call WOBURN, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2024 second quarter business and financial highlights before the opening of the market on August 6, 2024. The Company will host a conference call at 8:00 a.m., Eastern Time on August 6, 2024. For participants who wish to access the Q2 2024 Conference Call live via telephone and be able to ask questions, please register in advance here. Upon registering, a dial-in and uniqu GlobeNewswire ? 2 months ago NURO -1.65% NeuroMetrix Reports Q1 2024 Business Highlights WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2024. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. “We are focused on maximizing shareholder value,” said Shai N. Gozani, M.D., Ph.D., Chief Executive Officer of NeuroMetrix. “Shareholders have recently provided valuable insights in addition t GlobeNewswire ? 5 months ago NURO -1.65% NeuroMetrix, Inc.'s (NASDAQ:NURO) CEO Might Not Expect Shareholders To Be So Generous This Year Key Insights NeuroMetrix to hold its Annual General Meeting on 30th of April CEO Shai Gozani's total compensation... Simply Wall St. ? 5 months ago NURO -1.65% NeuroMetrix Announces Steps Taken to Enhance Shareholder Value Joshua S. Horowitz joins Board of DirectorsAt-the-market equity facility terminated WOBURN, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced two steps to enhance shareholder value following feedback and recommendations from one of its largest shareholders, Ephraim Fields of Echo Lake Capital. The Board has approved the appointment of Joshua S. Horowitz as a new independent director with a 1-year term. Mr. Horowitz is a professional investor with over 22 GlobeNewswire ? 6 months ago NURO -1.65% NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck? combined with standard EKG or DPNCheck alone accurately detects diabetic peripheral neuropathy (DPN). Hayashi and colleagues evaluated 167 patients with Type 1 or Type 2 diabetes. The reference standard for DPN was a gold standard nerve conduction study. The authors developed a predictive formula based on DPNCheck measurements, patient age GlobeNewswire ? 7 months ago NURO -1.65% NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell? Fibromyalgia WOBURN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022. “We have been pleased by the positive response to Quell Fibromyalgia from providers taking care of patients with fibromyalgia during our strategic launch phase,” said Shai N. Gozani, M.D., Ph.D., Chief Executive Officer of NeuroMetrix. “This early adoption affirms the GlobeNewswire ? 7 months ago NURO -1.65% Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired NURO stock price has declined 99% since its IPO Gozani has received compensation of over $10 million since the IPO Gozani was charged by the FTC for various wrongdoings at NURO Gozani apparently personally paid the FTC $4 million as part of a settlement ... ACCESSWIRE ? 7 months ago NURO -1.65% RS FUND LP Calls for Immediate Action and Capital Return in Neurometrix, Inc. Stock trades significantly below its net cash per share. The board is arguably in breach of their fiduciary responsibility to protect shareholder value. Operating any capital raise at current price is grossly irresponsible and against shareholders ... ACCESSWIRE ? 7 months ago NURO -1.65% Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc. - Stock trades significantly below its net cash per share - Questions the Board's ability and/or desire to create shareholder value - Notes tremendous destruction of shareholder value under company's leadership - Sees no reason for company to remain ... ACCESSWIRE ? 7 months ago NURO -1.65% NeuroMetrix Full Year 2023 Earnings: US$6.08 loss per share (vs US$4.96 loss in FY 2022) NeuroMetrix ( NASDAQ:NURO ) Full Year 2023 Results Key Financial Results Revenue: US$5.90m (down 28% from FY 2022). Net... Simply Wall St. ? 7 months ago NURO -1.65% NeuroMetrix, Inc. (NASDAQ:NURO) Q4 2023 Earnings Call Transcript NeuroMetrix, Inc. (NASDAQ:NURO) Q4 2023 Earnings Call Transcript February 22, 2024 NeuroMetrix, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to the NeuroMetrix Fourth Quarter 2023 Business and Financial Update. My name is Josh, and […] Insider Monkey ? 7 months ago NURO -1.65% Q4 2023 NeuroMetrix Inc Earnings Call Q4 2023 NeuroMetrix Inc Earnings Call Thomson Reuters StreetEvents ? 7 months ago NURO -1.65% NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights WOBURN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. "Quell? Fibromyalgia growth accelerated in Q4 2023 reflecting the addition in Q3 2023 of two field business development managers and optimized clinical messaging. We also int GlobeNewswire ? 7 months ago NURO -1.65% NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call WOBURN, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2023 fourth quarter and year end business and financial highlights before the opening of the market on February 22, 2024. The Company will host a conference call at 8:00 a.m., Eastern Time on February 22, 2024. For participants who wish to access the Q4 and year end 2023 Conference Call live via telephone and be able to ask questions, please register in advance here. Upon GlobeNewswire ? 8 months ago NURO -1.65% NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value WOBURN, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), a commercial stage medical device company focused on reducing the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices, today announced a process to review strategic options to promote growth of its Quell? neuromodulation and DPNCheck? neurodiagnostic businesses and to maximize shareholder value. The Company plans to consider a wide range of options, including changes GlobeNewswire ? 8 months ago NURO -1.65% Presenting on the Emerging Growth Conference 66 Day 1 on January 10 Register Now MIAMI, Jan. 09, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 66th Emerging Growth Conference on January 10 & 11, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting comp GlobeNewswire ? 9 months ago RFHRF YGTFF AMLI NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024 WOBURN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on January 10, 2024. This live, interactive, online event will give shareholders and the investment community the opportunity to interact in real time with the Company’s Chairman and Chief Executive Officer, Dr. Shai N. Gozani. Dr. Gozani will present business highlights and recent developments, including the evolution of its Quell? neuromodula GlobeNewswire ? 9 months ago NURO -1.65% Performance Overview Trailing total returns as of 10/25/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return NURO S&P 500 YTD +9.29% +22.24% 1-Year -24.34% +37.26% 3-Year -93.30% +28.29%
